CIBC World Markets Inc. Boosts Position in iShares NASDAQ Biotechnology Index (IBB)

CIBC World Markets Inc. increased its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 123.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,807 shares of the financial services provider’s stock after buying an additional 3,758 shares during the quarter. CIBC World Markets Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $727,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Traynor Capital Management Inc. grew its holdings in shares of iShares NASDAQ Biotechnology Index by 244.7% during the fourth quarter. Traynor Capital Management Inc. now owns 11,531 shares of the financial services provider’s stock valued at $1,231,000 after buying an additional 8,186 shares during the last quarter. Private Wealth Partners LLC purchased a new stake in shares of iShares NASDAQ Biotechnology Index during the fourth quarter valued at $272,000. Chatham Capital Group Inc. grew its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. Chatham Capital Group Inc. now owns 1,959 shares of the financial services provider’s stock valued at $209,000 after buying an additional 1,306 shares during the last quarter. SOL Capital Management CO grew its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. SOL Capital Management CO now owns 20,022 shares of the financial services provider’s stock valued at $2,138,000 after buying an additional 13,348 shares during the last quarter. Finally, Investment House LLC grew its holdings in shares of iShares NASDAQ Biotechnology Index by 206.5% during the fourth quarter. Investment House LLC now owns 30,990 shares of the financial services provider’s stock valued at $3,309,000 after buying an additional 20,880 shares during the last quarter. 27.28% of the stock is currently owned by hedge funds and other institutional investors.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $109.73 on Thursday. iShares NASDAQ Biotechnology Index has a 1-year low of $94.20 and a 1-year high of $119.30.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://weekherald.com/2018/02/15/cibc-world-markets-inc-raises-position-in-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply